阿昔洛韦联合胸腺肽抗乙肝病毒疗效观察

本文报道了阿昔洛韦联合胸腺肽对慢性乙型肝炎抗病毒疗效，阿昔洛韦１０ｇ，胸腺肽１６ｍｇ静滴，每日一次，连续治疗２月，共治疗３３例，治疗结束后，治疗组ＨＢｅＡｇ阴转１６例，阴转率５５１７％，ＨＢＶ ＤＮＡ阴转１８例，阴转率５４５４％。对照组ＨＢｅＡｇ阴转率９５２％（２／２５），ＨＢＶ ＤＶＡ阴转率９０９％（１／２５），两组比较有显著性差异（ｐ＜００１），表明阿昔洛韦联合胸腺肽是一种有效、价廉、使用方便的抗乙型肝炎病毒药物。     

无环鸟苷亲脂性前体药物脂质体的制备及体外抗病毒活性(英文)

本文通过将无环鸟苷(acyclovir,简称ACV)2’位羟基分别与月桂酰氯或棕榈酰氯进行酯化反应,制得亲脂性前体药物无环鸟苷月桂酸酯和无环鸟苷棕榈酸酯(分别简称为C₁₂-ACV和C₁₆-ACV),使脂质体包封率从ACV的29.9%提高到C₁₂-ACV的95.6%和C₁₆-ACV的97.1%;漏泄实验表明在4℃透析60h后,一半以上的ACV从脂质体中漏泄,而C₁₂-ACV和C₁₆-ACV的滞留率分别为70%和80%;体外抗疱疹病毒的试验中,在最低试验浓度0.044μmol/L时,ACV不显示抗病毒活性,而C₁₆-ACV脂质体抑制细胞病变率达75%,说明前体药物通过与脂质体脂膜的结合增加了药物的进入细胞能力,从而提高了ACV的抗病毒能力。     

口服阿昔洛韦在单疱病毒性角膜炎行角膜移植术后的应用

目的　评价单纯疱疹病毒性角膜炎患者行穿透性角膜移植术后,口服阿昔洛韦预防单纯疱疹病毒性角膜炎复发的疗效。方法　1999年1月至2 0 0 3年12月单纯疱疹病毒性角膜炎5 2例5 2眼行穿透性角膜移植术,术后给予口服阿昔洛韦2 0 0mg 5次/d ,服用2m～3m后减为4 0 0mg 2次/d ,继续服用3m后停止,分析单纯疱疹病毒性角膜炎复发的情况。结果　在口服阿昔洛韦期间,无一例出现单纯疱疹病毒性角膜炎的复发。术后经12m～38m (2 2 .8±9. 6 )的随访,4 9眼植片透明,3眼因排斥反应植片混浊。32眼(6 1 .5 % )最佳矫正视力好于0 . 5 ,4 9眼(94 . 2 % )最佳矫正视力好于0 . 1,3眼(5 . 8% )低于0 . 1。结论　口服阿昔洛韦能有效预防单纯疱疹病毒性角膜炎行穿透性角膜移植术后的复发     

慢性乙型肝炎的抗病毒治疗探讨

目的：探讨应用小剂量干扰素（IFN）联合阿昔洛韦（Acyclovir)、单用IFN、一般护肝治疗药物三种方法治疗慢性乙肝的疗效。方法：将选择的84例病人随机分为三组,联合组32例应用IFN lmu Acyclovir 0.75;单用组21例,应用IFN 3mn;护肝组31例,应用肝炎灵针4ml;疗程均为3个月。观察临床,ALT和病毒复制指标变化。结果：三组均能减轻或消除肝炎症状,改善肝功,ALT腹常率在治疗后2个月无明显差异。疗程结束后近期观察3个月,其HbeAg、HBVDNA阴转率及复发率,在联合组分别为46．2％、45．2％、6．7％,单用组分别为22．2％、28．6％、11．7％,护肝组分别为3．8％、3．2％、25．9％,有显差异。结论：小剂量干扰素联合阿昔洛韦治疗慢性乙肝具有与常规剂量干扰素同等的治疗效果。且副作用轻,治疗费用低。     

阿昔洛韦片在人体中药动力学及其相对生物利用度研究

目的比较两种阿昔洛韦片生物利用度和药代动力学。方法测定10名受试者单剂量交叉口服600mg阿昔洛韦受试片和参比片后血药浓度,计算相应的药代动力学参数。结果受试者口服两种阿昔洛韦片计算的峰浓度Cmax、Tmax和AUC分别为Cmax1.24±0.49和1.17±0.20μg/ml,Tmax1.9±0.6h和2.1±1.1h,AUC7.56±1.80和7.56±2.10μg     

Acyclovir treatment of relapsing-remitting multiple sclerosis

Acyclovir treatment was used in a randomized, double-blind, placebo-controlled clinical trial with parallel groups to test the hypothesis that herpes virus infections are involved in the pathogenesis of multiple sclerosis (MS). Sixty patients with the relapsing-remitting form of MS were randomized to either oral treatment with 800 mg acyclovir or placebo tablets three times daily for 2 years. The clinical effect was investigated by an extensive test battery consisting of neurological examinations, neuro-ophthalmological and neuropsychological tests, and evoked potentials. Results were based on intent-to-treat data and the primary outcome measure was the exacerbation rate. In the acyclovir group (n = 30), 62 exacerbations were recorded during the treatment period, yielding an annual exacerbation rate of 1.03. The placebo group (n = 30) had 94 exacerbations and an annual exacerbation rate of 1.57. Thus, 34% fewer exacerbations were encountered during acyclovir treatment. This difference in exacerbation rate between the treatment groups was not significant (P = 0.083). However, this trend to a lower disease activity in acyclovir-treated patients was supported in subsequent data analysis. If the patients were grouped according to exacerbation frequencies, i.e. into low (0–2), medium (3–5) and high (6–8) rate groups, the difference between acyclovir and placebo treatment was significant (P = 0.017). Moreover, in a subgroup of the population with a duration of the disease of at least 2 years providing an exacerbation rate base-line before entry, individual differences in exacerbation rates were compared between the 2-year pre-study period and the study period in acyclovir-treated (n = 19) and placebo (n = 20) patients and acyclovir-treated patients showed a significant reduction of exacerbations (P = 0.024). Otherwise, neurological parameters were essentially unaffected by acyclovir treatment and there were no convincing signs of reduced neurological deterioration in the acyclovir group. This study indicates that acyclovir treatment might inhibit the triggering of MS exacerbations and thus suggests that acyclovir-susceptible viruses might be involved in the pathogenesis of MS. This possibility warrants further investigation.     

复方甘草酸苷联合无环鸟苷治疗带状疱疹疗效观察

目的:观察复方甘草酸苷联合无环鸟苷治疗带状疱疹的疗效。方法:将98例带状疱疹患者随机分为治疗组(复方甘草酸苷+无环鸟苷)和对照组(无环鸟苷)。结果:治疗后症状、体征消退时间治疗组明显短于对照组(P<0.01);治疗组和对照组后遗神经痛发生率分别为6.10%、18.37%(P<0.01)。结论:复方甘草酸苷联合无环鸟苷治疗带状疱疹的疗效优于单用无环鸟苷。     

人体内阿昔洛韦血药浓度的HPLC测定

目的:建立阿昔洛韦血药浓度测定方法,用于阿昔洛韦缓释片血药浓度研究。方法:采用高效液相色谱法。分析柱为C1 8柱,流动相为2 %乙腈水溶液(p H3) ,检测波长2 5 4 nm。结果:样品组分在0 .0 5～1.0μg·ml- 1 线性良好(0 .9997) ,最低血浆药物检测浓度为0 .0 1μg·ml- 1。回收率为92 .36 %～99.2 1% ,日内及日间RSD<10 %。结论:本法简便、迅速、灵敏、准确,适合于临床药学研究需要。     

微波配合阿昔洛韦治疗女性生殖器疱疹的临床疗效

目的:探讨了微波配合阿昔洛韦治疗女性生殖器疱疹的疗效和安全性。方法:选择2010年3月～2011年3月女性生殖器疱疹患者36例,按照分层分组法随机分为两组,对照组和治疗组,对照组采用阿昔洛韦进行治疗,治疗组在对照组治疗基础上采用微波进行治疗。对两组治疗效果进行评定。结果:对照组和治疗组有效率分别为90.5%和60.0%,治疗组有效率明显高于对照组(P<0.05)。治疗组复发次数明显低于对照组(P<0.05)。两组均未出现不良反应。结论:微波配合阿昔洛韦治疗女性生殖器疱疹疗效显著,安全性较高,值得临床推广使用。